Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4+ T cells

AIDS

Volumn 27, Issue 1, 2013, Pages 29-37

  Beliakova Bethell, Nadejda ^a   Zhang, Jin X ^b   Singhania, Akul ^b   Lee, Vivian ^b   Terry, Valeri H ^b   Richman, Douglas D ^a,b,c   Spina, Celsa A ^a,c   Woelk, Christopher H ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

gene expression; histone deacetylase inhibitor; HIV; microarrays; primary CD4+ T cells; suberoylanilide hydroxamic acid; vorinostat

Indexed keywords

HISTONE ACETYLTRANSFERASE; MESSENGER RNA; MYC PROTEIN; TRANSCRIPTOME; TRANSFER RNA; VORINOSTAT;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION; GLUCONEOGENESIS; GLYCOLYSIS; HISTONE ACETYLATION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN RNA BINDING; TREATMENT DURATION; UPREGULATION;

APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HISTONE DEACETYLASE INHIBITORS; HIV-1; HUMANS; HYDROXAMIC ACIDS; MALE; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTOME; VIRUS REPLICATION;

EID: 84871554268     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835b3e26     Document Type: Article

References (46)

1. Demonté D, Quivy V, Colette Y, Van Lint C. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. Biochem Pharmacol 2004; 68:1231-1238. (Pubitemid 39094289)
2. Matalon S, Rasmussen TA, Dinarello CA. Histone deacetylase inhibitors for purging HIV-1 from latent reservoir. Mol Med 2011; 17:466-472.
3. Yin H, Zhang Y, Zhou X, Zhu H. Histonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells. Mol Biol Rep 2011; 38:5071-5078.
4. Contreras X, Schweneker M, Chen C-S, McCune JM, Deeks SG, Martin J, et al. SuberoylanilideHydroxamic Acid Reactivates HIV from Latently Infected Cells. J BiolChem2009; 284:6782-6789.
5. Ying H, Zhang Y, Lin S, Han Y, Zhu H-Z. Histone acetylase inhibitor Scriptaid reactivates latent HIV-1 promoter by inducing histone modification in in vitro latency cell lines. Int J Mol Med 2010; 26:265-272.
6. Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, Margolis DM. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS 2009; 23:1799-1806.
7. Shehu-Xhilaga M, Rhodes D, Wightman F, Liu HB, Solomon A, Saleh S, et al. The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells. AIDS 2009; 23:2047-2050.
8. Van Lint C, Emiliani S, Ott M, Verdin E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 1996; 15:1112-1120. (Pubitemid 26077840)
9. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous t-cell lymphoma. Oncologist 2007; 12:1247-1252. (Pubitemid 350106355)
10. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002; 16:695-714. (Pubitemid 35176854)
11. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009; 25:207-212.
12. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004; 18:1101-1108. (Pubitemid 38738509)
13. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487:482-485.
14. Colin L, Van Lint C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 2009; 6:111.
15. Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem 2005; 96:293-304. (Pubitemid 41437862)
16. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA, et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003; 63:4460-4471. (Pubitemid 36951018)
17. He LZ, Tolentino T, Grayson P, Zhong S, Warrell RP Jr, Rifkind RA, et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 2001; 108:1321-1330. (Pubitemid 33107760)
18. Marks P, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001; 13:477-483. (Pubitemid 33027900)
19. Wozniak MB, Villuendas R, Bischoff JR, Aparicio CB, Martínez Leal JF, de La Cueva P, et al. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous Tcell lymphoma. Haematologica 2010; 95:613-621.
20. LaBonte M, Wilson P, Fazzone W, Groshen S, Lenz H-J, Ladner R. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med Genomics 2009; 2:67.
21. Mariadason JM, Corner GA, Augenlicht LH. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 2000; 60:4561-4572. (Pubitemid 32103641)
22. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003; 2:151-163.
23. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 2004; 101:540-545. (Pubitemid 38084672)
24. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102:3697-3702. (Pubitemid 40354674)
25. Halsall J, Gupta V, O'Neill LP, Turner BM, Nightingale KP. Genes are often sheltered from the global histone hyperacetylation induced by HDAC inhibitors. PLoS One 2012; 7:e33453.
26. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102:673-678. (Pubitemid 40282724)
27. Chang J, Varghese DS, Gillam MC, Peyton M, Modi B, Schiltz RL, et al. Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide. Br J Cancer 2012; 106:116-125.
28. Moreira JM, Scheipers P, Sorensen P. The histone deacetylase inhibitor Trichostatin A modulates CD4R T cell responses. BMC Cancer 2003; 3:30.
29. Woelk CH, Beliakova-Bethell N, Goicoechea M, Zhao Y, Du P, Rought S, et al. Gene expression before HAART initiation predicts HIV-infected individuals at risk of poor CD4R T cell recovery. AIDS 2010; 24:217-222.
30. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y. Analysis of gene expression data using BRB-array tools. Cancer Informatics 2007; 3:11-17. (Pubitemid 47075796)
31. Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of Gene Ontology categories in Biological Networks. Bioinformatics 2005; 21:3448-3449. (Pubitemid 41222459)
32. De Jonge HJ, Fehrmann RS, de Bont ES, Hofstra RM, Gerbens F, Kamps WA, et al. Evidence based selection of housekeeping genes. PLoS One 2007; 2:e898.
33. Chana G, Lucero G, Salaria S, Lozach J, Du P, Woelk C, et al. Upregulation of NRG-1 and VAMP-1 in human brain aggregates exposed to clozapine. Schizophrenia Res 2009; 113:273-276.
34. Cummings RD, Liu F-T. Essentials of glycobiology. In: Varki A, Cummings RD, Esko JD, et al., editors. New York: Cold Spring Harbor Laboratory Press; 2009.
35. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006; 203:2691-2702. (Pubitemid 44833345)
36. Wardell SE, Ilkayeva OR, Wieman HL, Frigo DE, Rathmell JC, Newgard CB, et al. Glucose metabolism as a target of histone deacetylase inhibitors. Mol Endocrinol 2009; 23:388-401.
37. Frank SR, Parisi T, Taubert S, Fernandez P, Fuchs M, Chan H-M, et al. MYC recruits the TIP60 histone acetyltransferase complex to chromatin. EMBO 2003; 4:575-580. (Pubitemid 36939948)
38. McMahon SB, Wood MA, Cole MD. The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. Mol Cell Biol 2000; 20:556-562. (Pubitemid 30023097)
39. Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol 2001; 3:392-399. (Pubitemid 32288447)
40. Gartel AL, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F, et al. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci USA 2001; 98:4510-4515. (Pubitemid 32295007)
41. Satou A, Taira T, Iguchi-Ariga SMM, Ariga H. A novel transrepression pathway of c-Myc. J Biol Chem 2001; 276:46562-46567.
42. Jiang G, Espeseth A, Hazuda DJ. Margolis DM. c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol 2007; 81:10914-10923. (Pubitemid 47536066)
43. Delmore Jake E, Issa Ghayas C, Lemieux Madeleine E, Rahl Peter B, Shi J, Jacobs Hannah M, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146:904-917.
44. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci 2011; 108:16669-16674.
45. Banerjee C, Archin N, Michaels D, Belkina AC, Denis GV, Bradner J, et al. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukocyte Biol 2012. doi:10. 1189/jlb. 0312165
46. Mann BS, Johnson JR, He K, Sridhara R, Abraham S, Booth BP, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous t-cell lymphoma. Clin Cancer Res 2007; 13:2318-2322. (Pubitemid 46698579)